The effort, led by Shoukhrat Mitalipov of Oregon Health and Science University in the US, involved changing the DNA of a large number of one-cell embryos with the controversial gene-editing technique CRISPR.
Previous reports of editing human embryos were all by scientists in China.
For ethical reasons, the embryos were not allowed to develop for more than a few days.
The experiments are a milestone in journey towards the birth of the first genetically modified humans, according to the 'MIT Technology Review'.
The genetically modified child would then pass the changes on to subsequent generations.
Critics say that such experiments may open the gates to a world of "designer babies" engineered with genetic enhancements - a prospect opposed by religious organisations, civil society groups, and biotech companies.
"So far as I know this will be the first study reported in the US," said Jun Wu from the Salk Institute in the US, who was involved in the project.
Disclaimer: No Business Standard Journalist was involved in creation of this content
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors


Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share


Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor


Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements


Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
